tetano
Editor, Senior Moderator
Vaccine. 2010 Nov 26. [Epub ahead of print]
Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective.
Abelin A, Colegate T, Gardner S, Hehme N, Palache A.
The International Federation of Pharmaceutical Manufacturers and Associations International Vaccine Supply taskforce (IFPMA IVS), 15 Chemin Louis-Dunant, PO Box 195, 1211 Geneva 20, Switzerland.
Abstract
As A(H1N1) influenza moves towards the post-pandemic phase, health authorities around the world are initiating reviews of the pandemic response. To ensure this process enhances future preparedness, it is essential that perspectives are included from all relevant stakeholders, including vaccine manufacturers. This paper outlines the contribution of R&D-based influenza vaccine manufacturers to the pandemic response, and explores lessons that can be learned to improve future preparedness. The emergence of 2009 A(H1N1) influenza led to unprecedented collaboration between global health authorities, scientists and manufacturers, resulting in the most comprehensive pandemic response ever undertaken. This response was only possible because of the extensive preparations undertaken during the last decade. Manufacturers greatly increased influenza vaccine production capacity, and estimates suggest a further doubling of capacity by 2014. Producers also introduced cell-culture technology as well as adjuvant- and whole virion technologies that significantly reduced pandemic vaccine antigen content. These measures substantially increased pandemic vaccine production capacity, which in July 2009 WHO estimated reached 4.9 billion doses per annum. Manufacturers worked with health authorities to establish risk management plans for robust vaccine surveillance during the pandemic. A number of improvements would strengthen future preparedness. Technical improvements to rapidly select optimal vaccine viruses, and processes to speed. up vaccine standardization, would accelerate and extend vaccine availability. Establishing vaccine supply agreements beforehand would avoid the need for complex discussions during a period of intense time pressure. Enhancing international regulatory co-operation, mutual recognition of approvals and bureaucracy reduction could accelerate vaccine supply, while maintaining safety standards. Strengthening communications with the public and healthcare workers using new approaches and new channels should help improve vaccine uptake. Increasing seasonal vaccine coverage could extend and sustain pandemic vaccine production capacity.
Copyright ? 2010. Published by Elsevier Ltd.
PMID: 21115061 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21115061
Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective.
Abelin A, Colegate T, Gardner S, Hehme N, Palache A.
The International Federation of Pharmaceutical Manufacturers and Associations International Vaccine Supply taskforce (IFPMA IVS), 15 Chemin Louis-Dunant, PO Box 195, 1211 Geneva 20, Switzerland.
Abstract
As A(H1N1) influenza moves towards the post-pandemic phase, health authorities around the world are initiating reviews of the pandemic response. To ensure this process enhances future preparedness, it is essential that perspectives are included from all relevant stakeholders, including vaccine manufacturers. This paper outlines the contribution of R&D-based influenza vaccine manufacturers to the pandemic response, and explores lessons that can be learned to improve future preparedness. The emergence of 2009 A(H1N1) influenza led to unprecedented collaboration between global health authorities, scientists and manufacturers, resulting in the most comprehensive pandemic response ever undertaken. This response was only possible because of the extensive preparations undertaken during the last decade. Manufacturers greatly increased influenza vaccine production capacity, and estimates suggest a further doubling of capacity by 2014. Producers also introduced cell-culture technology as well as adjuvant- and whole virion technologies that significantly reduced pandemic vaccine antigen content. These measures substantially increased pandemic vaccine production capacity, which in July 2009 WHO estimated reached 4.9 billion doses per annum. Manufacturers worked with health authorities to establish risk management plans for robust vaccine surveillance during the pandemic. A number of improvements would strengthen future preparedness. Technical improvements to rapidly select optimal vaccine viruses, and processes to speed. up vaccine standardization, would accelerate and extend vaccine availability. Establishing vaccine supply agreements beforehand would avoid the need for complex discussions during a period of intense time pressure. Enhancing international regulatory co-operation, mutual recognition of approvals and bureaucracy reduction could accelerate vaccine supply, while maintaining safety standards. Strengthening communications with the public and healthcare workers using new approaches and new channels should help improve vaccine uptake. Increasing seasonal vaccine coverage could extend and sustain pandemic vaccine production capacity.
Copyright ? 2010. Published by Elsevier Ltd.
PMID: 21115061 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21115061